Achilles Therapeutics has sold certain technology assets to drug giant AstraZeneca for $12 million following a review of strategic alternatives by the clinical-stage biopharmaceutical company.
(RTTNews) - Achilles Therapeutics Plc. (ACHL), Tuesday announced that the company has transferred the commercial license of data and samples from the TRACERx Non-Small Cell Lung Cancer study to ...
Achilles Therapeutics (ACHL) announced that it has transferred the commercial license of data and samples from the TRACERx Non-Small Cell Lung Cancer study to AstraZeneca (AZN). TRACERx ...